TCG Labs-Soleil
Weijie Wang is a seasoned professional in the field of Chemistry with a Ph.D. from the University of Alberta, obtained between 1999 and 2004. Currently serving as Sr. Director of CMC & Analytical Development at Oncternal Therapeutics since April 2021, Weijie has held significant roles in various organizations, including Director positions at both Gilead Sciences and Forty Seven Inc., as well as Director of Analytical Development at Incyte. Previous experience includes serving as Principal Scientist at Teva Pharmaceuticals and Sr. Scientist I at Human Genome Sciences, along with a role as Scientist at Calibrant Biosystems.
This person is not in any teams
TCG Labs-Soleil
At TCG Labs-Soleil, we are establishing a pioneering venture-biotech model in collaboration with The Column Group. Our mission is to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases. Our approach integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub led by top-tier scientists (Soleil). This creates a powerful ecosystem forming and overseeing independent portfolio companies, each dedicated to single-asset biologic programs, guiding them from ideation to clinical proof of concept and positioning them for strategic partnerships and transformative medical advancements.